Trial Profile
Real-world observational study to investigate the tolerability of Gardasil in Californian females.
Status:
Not stated
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2011
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Therapeutic Use
- Sponsors Merck & Co
- 11 May 2011 New trial record
- 09 May 2011 Results were reported at the European Research Organization on Genital Infection and Neoplasia (EUROGIN).